Definitions of pulmonary exacerbation in people with cystic fibrosis: a scoping review

被引:0
|
作者
Almulhem, Maryam [1 ,2 ]
Ward, Christopher [1 ]
Haq, Iram [1 ,3 ]
Gray, Robert D. [4 ]
Brodlie, Malcolm [1 ,3 ]
机构
[1] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, England
[2] King Faisal Univ, Coll Appl Med Sci, Al Hasa, Saudi Arabia
[3] Newcastle Tyne Hosp NHS Fdn Trust, Great North Childrens Hosp, Paediat Resp Med, Newcastle Upon Tyne, England
[4] Univ Glasgow, Sch Infect & Immun, Glasgow, Scotland
关键词
pulmonary exacerbation; cystic fibrosis; definition; QUALITY-OF-LIFE; CHILDREN; ADULTS; TRIAL; AZITHROMYCIN; RATIONALE; FREQUENCY; OUTCOMES; DESIGN; FEV1;
D O I
10.1136/bmjresp-2024-002456
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Pulmonary exacerbations (PExs) are clinically important in people with cystic fibrosis (CF). Multiple definitions have been used for PEx, and this scoping review aimed to identify the different definitions reported in the literature and to ascertain which signs and symptoms are commonly used to define them.Methods A search was performed using Embase, MEDLINE, Cochrane Library, Scopus and CINAHL. All publications reporting clinical trials or prospective observational studies involving definitions of PEx in people with CF published in English from January 1990 to December 2022 were included. Data were then extracted for qualitative thematic analysis.Results A total of 14 039 records were identified, with 7647 titles and abstracts screened once duplicates were removed, 898 reviewed as full text and 377 meeting the inclusion criteria. Pre-existing definitions were used in 148 publications. In 75% of papers, an objective definition was used, while 25% used a subjective definition, which subcategorised into treatment-based definitions (76%) and those involving clinician judgement (24%). Objective definitions were subcategorised into three groups: those based on a combination of signs and symptoms (50%), those based on a predefined combination of signs and symptoms plus the initiation of acute treatment (47%) and scores involving different clinical features each with a specific weighting (3%). The most common signs and symptoms reported in the definitions were, in order, sputum production, cough, lung function, weight/appetite, dyspnoea, chest X-ray changes, chest sounds, fever, fatigue or lethargy and haemoptysis.Conclusion We have identified substantial variation in the definitions of PEx in people with CF reported in the literature. There is a requirement for the development of internationally agreed-upon, standardised and validated age-specific definitions. Such definitions would allow comparison between studies and effective meta-analysis to be performed and are especially important in the highly effective modulator therapy era in CF care.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Exercise as a therapeutic intervention for people with cystic fibrosis
    Ward, Nathan
    Stiller, Kathy
    Holland, Anne E.
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2019, 13 (05) : 449 - 458
  • [42] Azithromycin for improving pulmonary function in cystic fibrosis
    Carr, RR
    Nahata, MC
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (09) : 1520 - 1524
  • [43] Mental health care needs in cystic fibrosis: A scoping review
    Tickner, Campbell
    Holland, Lucy
    Wark, Peter
    Hilton, Jodi
    Morrison, Cathy
    Kay-Lambkin, Frances
    Heinsch, Milena
    SOCIAL WORK IN HEALTH CARE, 2022, 61 (02) : 108 - 122
  • [44] Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis
    VanDevanter, D. R.
    Heltshe, S. L.
    Spahr, J.
    Beckett, V. V.
    Daines, C. L.
    Dasenbrook, E. C.
    Gibson, R. L.
    Jain, R.
    Sanders, D. B.
    Goss, C. H.
    Flume, P. A.
    JOURNAL OF CYSTIC FIBROSIS, 2017, 16 (05) : 607 - 615
  • [45] Does Cefiderocol Have a Potential Role in Cystic Fibrosis Pulmonary Exacerbation Management?
    Gavioli, Elizabeth Marie
    Guardado, Nerli
    Haniff, Farah
    Deiab, Nouran
    Vider, Etty
    MICROBIAL DRUG RESISTANCE, 2021, 27 (12) : 1726 - 1732
  • [46] Sputum club cell protein concentration is associated with pulmonary exacerbation in cystic fibrosis
    Laguna, Theresa A.
    Williams, Cynthia B.
    Brandy, Kyle R.
    Welchlin-Bradford, Cole
    Moen, Catherine E.
    Reilly, Cavan S.
    Wendt, Christine H.
    JOURNAL OF CYSTIC FIBROSIS, 2015, 14 (03) : 334 - 340
  • [47] Characteristics associated with cystic fibrosis-related pulmonary exacerbation treatment location
    Gold, Laura S.
    Hansen, Ryan N.
    Heltshe, Sonya L.
    Flume, Patrick A.
    Goss, Christopher H.
    West, Natalie E.
    Sanders, Don B.
    Kessler, Larry
    JOURNAL OF CYSTIC FIBROSIS, 2024, 23 (02) : 278 - 281
  • [48] Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment
    Cogen, Jonathan D.
    Faino, Anna, V
    Onchiri, Frankline
    Gibson, Ronald L.
    Hoffman, Lucas R.
    Kronman, Matthew P.
    Rosenfeld, Margaret
    Nichols, David P.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2021, 18 (02) : 266 - 272
  • [49] Return of FEV1 After Pulmonary Exacerbation in Children With Cystic Fibrosis
    Sanders, Don B.
    Hoffman, Lucas R.
    Emerson, Julia
    Gibson, Ronald L.
    Rosenfeld, Margaret
    Redding, Gregory J.
    Goss, Christopher H.
    PEDIATRIC PULMONOLOGY, 2010, 45 (02) : 127 - 134
  • [50] Intravenous fosfomycin for pulmonary exacerbation of cystic fibrosis: Real life experience of a large adult CF centre
    Spoletini, G.
    Kennedy, M.
    Flint, L.
    Graham, T.
    Etherington, C.
    Shaw, N.
    Whitaker, P.
    Denton, M.
    Clifton, I.
    Peckham, D.
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2018, 50 : 82 - 87